Home > Riviste > Journal of Neurosurgical Sciences > Fascicoli precedenti > Articles online first > Journal of Neurosurgical Sciences 2016 Feb 19



Per citare questo articolo


Rivista di Neurochirurgia

Indexed/Abstracted in: e-psyche, EMBASE, PubMed/MEDLINE, Neuroscience Citation Index, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,522



Journal of Neurosurgical Sciences 2016 Feb 19


lingua: Inglese

Higher serum pentosidine, an advanced glycation end product, in branch atheromatous disease among small vessels occlusion

Toshiki IKEDA 1, 4, Keisuke MARUYAMA 4, Nobuyuki ITO 2, 4, Akira UTAGAWA 2, 5, Atsushi SHIMADA 3, 4, Yoshiaki SHIOKAWA 4, Hiroki KURITA 1, 4

1 Department of Cerebrovascular Surgery and Stroke Center, International Medical Center, Saitama Medical University, Saitama-Pref., Japan; 2 Department of Neurosurgery, Akiru Municipal Medical Center, Tokyo, Japan; 3 Department of Neurosurgery, Sasa General Hospital, Tokyo, Japan; 4 Department of Neurosurgery, Kyorin University Faculty of Medicine, Tokyo, Japan; 5 Department of Emergency and Critical Care Medicine, Nihon University School of Medicine, Tokyo, Japan


BACKGROUND: Cerebral branch atheromatous disease (BAD) are more likely to experience progressing stroke and neurological deterioration compared with lacunar infarction, although these small vessels occlusions are difficult to discriminate in acute phase of ischemic stroke. Advanced glycation end products including pentosidine have been implicated in atherosclerosis, and were associated with atheroma plaque progression. However, little is known about a relationship between serum pentosidine and small vessels occlusion.
METHODS: Serum pentosidine levels were measured in 56 patients (BAD, 21; lacunar, 35) with small vessels occlusion among consecutive 208 patients with acute ischemic stroke at initial hospitalization as well as other risk factors of stroke. Univariate and multivariate logistic regression analyses were performed to analyze relationship between risk factors including pentosidine and small vessels occlusion. Sensitivity and selectivity of pentosidine to discriminate BAD from lacunar were calculated.
RESULTS: Serum pentosidine was significantly higher in BAD group than lacunar group (0.081 ± 0.081μg/ml and 0.046 ± 0.043μg/ml, p < 0.05). In the univariate logistic regression analyses, BAD was significantly related to high serum pentosidine (p = 0.01), absence of dyslipidemia (p = 0.04), and worse outcome measured by modified Rankin Scale (p = 0.03). Multivariate logistic regression analysis showed that only high level of serum pentosidine was the independent risk factor for BAD (p = 0.03). Sensitivity and specificity were 90% and 44%, respectively.
CONCLUSIONS: High level of serum pentosidine in acute phase of stroke was associated with BAD, which led to worse outcome among patients with small vessels occlusion.

inizio pagina

Publication History

Per citare questo articolo

Ikeda T, Maruyama K, Ito N, Utagawa A, Shimada A, Shiokawa Y, et al. Higher serum pentosidine, an advanced glycation end product, in branch atheromatous disease among small vessels occlusion. J Neurosurg Sci 2016 Feb 19. 

Corresponding author e-mail